Investment case
CVS Health Corporation
CVS · 29 developments mapped · last assessed 2026-09-27
Market Ontology has mapped 29 macro, policy, and market developments to CVS Health Corporation since 2026-08-30. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.
Valuation
No validated run has been published for CVS yet, so no modelled value is shown. The CVS valuation is in the public catch-up queue.
Subscribers do not wait for the weekly cycle: they run CVS on demand, against live prices and the latest filings, and change any assumption the developments below move.
Filed financials
Current case
- Strongest support
Eli Lilly generates $27.7B in 1H GLP-1 sales as Foundayo gains PBM formulary
Increased prescription volume and formulary management fees for GLP-1 drugs, particularly with new oral treatments gaining PBM access.
· Moves pharmacy services revenue growth, pbm profitability
- Open question
NexLife Launches Flat-Rate $119-$169 Compounded GLP-1 Programs Across Doses
Potential for increased prescription volume for GLP-1 drugs (both branded and compounded) through its pharmacy benefit management (PBM) and retail pharmacy segments, but also pressure on PBM margins if compounded options gain significant traction.
· Moves pharmacy script volume growth, pbm rebate dynamics, healthcare services utilization
What changed, by assumption
- 2026-09-18Eli Lilly generates $27.7B in 1H GLP-1 sales as Foundayo gains PBM formulary
- 2026-09-18Eli Lilly GLP-1 revenue reaches $27.7B in H1 2026 as oral obesity drug expands coverage
- 2026-09-18Eli Lilly GLP-1 revenue reaches $27.7B in 1H 2026 as oral Foundayo expands PBM coverage
- 2026-09-18Eli Lilly H1 GLP-1 sales reach $27.7B as oral obesity pill Foundayo secures PBMs
- 2026-08-30Eli Lilly GLP-1 Revenue Hits Nearly Two-Thirds of Sales Amid 45% Top-Line Growth
- 2026-09-18Eli Lilly GLP-1 Franchise Hits $27.7B in H1 2026 as Foundayo Gains PBM Coverage
- 2026-09-18Eli Lilly GLP-1 Revenue Hits $27.7B in 1H 2026 as Oral Foundayo Expands
- 2026-09-18Eli Lilly GLP-1 Revenue Hits $27.7B in 1H 2026 as Oral Foundayo Expands
Assumption changes
Full ledger →| Date | Assumption | Direction | Why | Conf. |
|---|---|---|---|---|
| 2026-07-09 | Margin | Bearish | HHS OIG report on prior-authorization practices increases regulatory and legal risk for the company's Medicare Advantage segment. | 0.75 |
Event impact log
Full ledger →| Date | Mechanism | Direction | Horizon | Impact |
|---|---|---|---|---|
| 2026-09-27 | US National Debt Crosses $40 Trillion as Annual Interest Reaches $1.25 Trillion | watch | 3-12m | 0.40 |
| 2026-09-23 | Novo Nordisk Rebrands to Novo and Prepares Oral GLP-1 Launch Against Eli Lilly | Bullish | 1-3m | 0.40 |
| 2026-09-23 | Novo Rebrands to 'Novo' and Launches Oral GLP-1 Pill in Obesity Market Push | Bullish | 1-3m | 0.40 |
| 2026-09-23 | Novo Rebrands to 'Novo' and Deploys Oral GLP-1 Pill in Market Share Defense | mixed | 3-12m | 0.50 |
| 2026-09-22 | Tonix Pharmaceuticals Announces Second Major Managed Medicare Payer Agreement for TONMYA | watch | 3-12m | 0.20 |
| 2026-09-19 | Teva Highlights Real-World Data Demonstrating UZEDY Superiority in Treatment Continuity | mixed | 3-12m | 0.40 |
| 2026-09-19 | Teva real-world data demonstrates UZEDY reduces emergency care and medical costs | Bullish | 1-5y | 0.30 |
| 2026-09-19 | Teva Clinical Evidence Highlights UZEDY Treatment Retention and Cost Reductions | mixed | 3-12m | 0.50 |
| 2026-09-19 | Teva Real-World Data Shows UZEDY Lowers Emergency Healthcare Utilization | mixed | 3-12m | 0.40 |
| 2026-09-18 | Centene Posts $2.51 Q2 EPS as Medical Cost Turnaround Offsets 8%-9% Medicaid Shrinkage | watch | 3-12m | 0.30 |
| 2026-09-18 | Eli Lilly generates $27.7B in 1H GLP-1 sales as Foundayo gains PBM formulary | Bullish | 1-3m | 0.70 |
| 2026-09-18 | Eli Lilly GLP-1 revenue reaches $27.7B in 1H 2026 as oral Foundayo expands PBM coverage | Bullish | 1-3m | 0.70 |